Trudel D - Search Results

1

Matrix metalloproteinase 9 is associated with Gleason score in prostate cancer but not with prognosis.

Trudel D, Fradet Y, Meyer F, Têtu B. Trudel D, et al. Hum Pathol. 2010 Dec;41(12):1694-701. doi: 10.1016/j.humpath.2010.05.001. Epub 2010 Sep 9. Hum Pathol. 2010. PMID: 20825973

2

Detection of SARS-CoV-2 in saliva by a low-cost LSPR-based sensor.

Bido AT, Ember KJI, Trudel D, Durand M, Leblond F, Brolo AG. Bido AT, et al. Among authors: trudel d. Anal Methods. 2023 Aug 17;15(32):3955-3966. doi: 10.1039/d3ay00853c. Anal Methods. 2023. PMID: 37530390

3

Significance of MMP-2 expression in prostate cancer: an immunohistochemical study.

Trudel D, Fradet Y, Meyer F, Harel F, Têtu B. Trudel D, et al. Cancer Res. 2003 Dec 1;63(23):8511-5. Cancer Res. 2003. PMID: 14679018

4

The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis.

Têtu B, Brisson J, Wang CS, Lapointe H, Beaudry G, Blanchette C, Trudel D. Têtu B, et al. Among authors: trudel d. Breast Cancer Res. 2006;8(3):R28. doi: 10.1186/bcr1503. Epub 2006 Jun 15. Breast Cancer Res. 2006. PMID: 16776850 Free PMC article.

5

[Proteases by reactive stromal cells in cancer: an attractive therapeutic target].

Têtu B, Trudel D, Wang CS. Têtu B, et al. Among authors: trudel d. Bull Cancer. 2006 Sep;93(9):944-8. Bull Cancer. 2006. PMID: 16980237 Free article. Review. French.

6

Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: identification of patients with poor prognosis by immunohistochemistry.

Trudel D, Fradet Y, Meyer F, Harel F, Têtu B. Trudel D, et al. Hum Pathol. 2008 May;39(5):731-9. doi: 10.1016/j.humpath.2007.09.021. Epub 2008 Mar 10. Hum Pathol. 2008. PMID: 18329693

7

Green tea for ovarian cancer prevention and treatment: a systematic review of the in vitro, in vivo and epidemiological studies.

Trudel D, Labbé DP, Bairati I, Fradet V, Bazinet L, Têtu B. Trudel D, et al. Gynecol Oncol. 2012 Sep;126(3):491-8. doi: 10.1016/j.ygyno.2012.04.048. Epub 2012 May 4. Gynecol Oncol. 2012. PMID: 22564714 Review.

8

Human epididymis protein 4 (HE4) and ovarian cancer prognosis.

Trudel D, Têtu B, Grégoire J, Plante M, Renaud MC, Bachvarov D, Douville P, Bairati I. Trudel D, et al. Gynecol Oncol. 2012 Dec;127(3):511-5. doi: 10.1016/j.ygyno.2012.09.003. Epub 2012 Sep 9. Gynecol Oncol. 2012. PMID: 22967799

9

A two-stage, single-arm, phase II study of EGCG-enriched green tea drink as a maintenance therapy in women with advanced stage ovarian cancer.

Trudel D, Labbé DP, Araya-Farias M, Doyen A, Bazinet L, Duchesne T, Plante M, Grégoire J, Renaud MC, Bachvarov D, Têtu B, Bairati I. Trudel D, et al. Gynecol Oncol. 2013 Nov;131(2):357-61. doi: 10.1016/j.ygyno.2013.08.019. Epub 2013 Aug 27. Gynecol Oncol. 2013. PMID: 23988418 Clinical Trial.

10

Downgrading of biopsy based Gleason score in prostatectomy specimens.

Treurniet KM, Trudel D, Sykes J, Evans AJ, Finelli A, Van der Kwast TH. Treurniet KM, et al. Among authors: trudel d. J Clin Pathol. 2014 Apr;67(4):313-8. doi: 10.1136/jclinpath-2012-201323. Epub 2013 Oct 29. J Clin Pathol. 2014. PMID: 24403214

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

94 results

Search Page

Filters